0000000000207905

AUTHOR

Nerina Denaro

showing 2 related works from this author

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: literature review and consensus

2015

Abstract: The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a revie…

cancer patientpathogenesipositron emission tomographyhealthcare associated infectionSettore MED/06 - Oncologia Medicapatient monitoringradiodiagnosimedicine.medical_treatmentChemotherapy; Head and neck cancer; Radiotherapy; SepsisthrombocytopeniaReviewblood cultureorgan injurymedical terminologyMedicineHead and neck cancermetabolic acidosiC reactive proteinHead and Neck Neoplasmmedical specialisttreatment withdrawalconsensus developmentHematologyclinical practicesystemic inflammatory response syndromeItalyOncologyHead and Neck Neoplasmslaboratory testthrombocytosichemically induced/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingchemotherapy; head and neck cancer; radiotherapy; sepsis; oncology; hematology; geriatrics and gerontologyorgan perfusionhospitalizationHumansepsis Head and Neck Neoplasmmedicine.medical_specialtySettore MED/17 - Malattie InfettiveSepsibacterium culturediagnostic approach routefluorodeoxyglucosecancer chemotherapySepsisSDG 3 - Good Health and Well-beingSepsiscancer radiotherapyfollow upChemotherapyHumansinfection riskIntensive care medicineprocalcitonin antimicrobial therapyChemotherapyRadiotherapybusiness.industrydisease predispositionHead and neck cancerlactic acidChemotherapy; Head and neck cancer; Radiotherapy; Sepsis; Humans; Italy; Head and Neck Neoplasms; Sepsis; Hematology; Oncology; Geriatrics and Gerontologymedicine.diseasemortalityDelphi studyRadiation therapyinflammationincidencehyperglycemiaHuman medicineGeriatrics and Gerontologybusiness
researchProduct

Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives.

2009

Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.

DrugOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmolecular markersmedia_common.quotation_subjectgefitinibAntineoplastic AgentsGefitinibcancer therapyGefitinibCarcinoma Non-Small-Cell LungInternal medicinetyrosine kinase inhibitorsmedicineAnimalsHumansgefitinib; non-small cell lung cancer (NSCLC); epidermal growth factor receptor (HER1/EGFR); tyrosine kinase inhibitors; target therapy; molecular markers; EGFR mutationsEpidermal growth factor receptorLung cancermedia_commonPharmacologyClinical Trials as Topicbiologybusiness.industrytarget therapymedicine.diseaseEGFR mutationsepidermal growth factor receptor (HER1/EGFR)ErbB Receptorsnon-small cell lung cancer (NSCLC)OncologyQuinazolinesbiology.proteinMolecular MedicineSignal transductionbusinessBiomarkersEgfr tyrosine kinaseSignal Transductionmedicine.drug
researchProduct